
News|Articles|July 16, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
- Volume 11
- Issue 8
EMA Releases API Bioequivalence Studies Guidance
Author(s)Pharmaceutical Technology Editors
The agency has released guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin, and zonisamide.
Advertisement
The European Medicines Agency (EMA) opened up for consultation product-specific guidance documents on bioequivalence studies for the active substances asenapine, prasugrel, sitagliptin, and zonisamide. The release of the guidance documents follows finalization of bioequivalence guidance on 16 active substances in 2014 and 2015.
Articles in this issue
over 11 years ago
CDMOs Move Slowly with Expansion Plansover 11 years ago
Accelerating Continuous API Synthesisover 11 years ago
BioOutsource Opens New Facility in Glasgowover 11 years ago
Silicone Rubber Pieces Spur Recall of Teva Productover 11 years ago
Baxter Recalls IV Solution for Container and Particulate Issuesover 11 years ago
Indian API Manufacturer Cited for Recordkeeping Failuresover 11 years ago
Xcelience Makes Investment in Powdersizeover 11 years ago
FDA Issues Quality Metrics Draft Guidance Document for Commentover 11 years ago
EMA Issues Guideline on Fast Tracking Drugs for Unmet NeedsAdvertisement
Related to this article

FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.

Trump withdraws FDA commissioner nominee Heidi Overton, extending a leadership gap that leaves review and launch timelines uncertain for sponsors.

The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance

The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.

The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.

The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.

The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Challenges in Oral Delivery of Peptides: Bioavailability
2
AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis
3
Neladalkib Accelerated Approval: What ALK Drug Developers Should Know
4
Manufacturing Intelligence: Where Pharma Should Slow AI
5


